GlobeNewswire

Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
12/11/2026
Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027 Positive denifanstat Phase 3 clinical trial results in [...]
Profusa Announces Progress Towards Satisfying the Conditions to Close of the Option Agreement with G3
12/11/2026
PCAOB audited FY2024 and FY2025 and reviewed unaudited six months ended June 30, 2026 financials of G3 and its consolidated subsidiaries (“G3”) delivered In FY 2025, the Combined G3 company had consolidated revenue of $ [...]
Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference
12/11/2026
WAYNE, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials
12/11/2026
BD200 is a multibody drug conjugate, in which each arm of the antibody can alternatively bind to either Nectin-4 or Trop2, two validated oncology antigens that may be expressed on cancer cells Combined with a unique [...]
123Dentist CEO Jeff Leger and family establish fund at Dalhousie University’s Faculty of Dentistry to advance research into the connection between oral health and overall health
12/11/2026
The Leger Family Oral Health Research Fund will back research that deepens understanding of how oral health connects to overall health and chronic disease TORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Jeff Leger, Chief [...]
Jeff Leger, président-directeur général de 123Dentiste, et sa famille créent un fonds à la Faculté de médecine dentaire de l’Université Dalhousie pour mieux comprendre le lien entre santé buccodentaire et santé globale
12/11/2026
Le Fonds de recherche en santé buccodentaire de la famille Leger soutiendra des travaux visant à mieux comprendre les liens entre la santé buccodentaire, la santé globale et les maladies chroniques TORONTO, 12 nov. 2026 [...]
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
12/11/2026
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027 TSHA-102 continues to be [...]
NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations
12/11/2026
New insider filings show continued open-market buying by CEO Amir Heshmatpour, while the company prepares to discuss a potential accelerated approval strategy and Phase 3 trial design with regulators DENVER, Nov. 12, [...]
Olema Oncology Announces Corporate Name Change
12/11/2026
SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the [...]
LiveWorld Reports Third Quarter 2026 Financial Results
12/11/2026
LiveWorld accelerates its AI investment CAMPBELL, Calif. and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for third quarter 2026. Three Months 2026 [...]
Olympia Pharmaceuticals to Compound Select Peptides Under HHS Interim Enforcement Policy
12/11/2026
503A pharmacy will begin compounding BPC-157, with plans to expand across eligible peptides ORLANDO, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals , a premier FDA-registered 503B outsourcing facility [...]
Medicana Expert Highlights: New Study Finds Better One-Year Outcomes After Robot-Assisted Knee Replacement
12/11/2026
The research involving 845 patients found improvements in pain, knee function and patient satisfaction, drawing attention to the role of personalised surgical planning in joint replacement ISTANBUL, Nov. 12, 2026 (GLOBE [...]
Alps Group Inc Launches Pharmaco-Interaction (PCI) Unit via MyGenome, Debuting with CYP450 Drug Interaction Testing
12/11/2026
PCI Positions MyGenome as Southeast Asia's Reference Laboratory for Drug Interaction Safety Science KUALA LUMPUR, Malaysia, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an [...]
Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
12/11/2026
~ Third Quarter 2026 Net Product Sales of $19.4 Million, Up 56% Year over Year ~ ~ Third Quarter 2026 Non-GAAP Adjusted EBITDA of $5.8 Million ~ ~ With $6.7 Million in Positive Cash Flow from Operations, Cash Position [...]
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
12/11/2026
New Drug Application (NDA) for tinlarebant in Stargardt disease type 1 (STGD1) granted priority review by the U.S. Food and Drug Administration (FDA) in August 2026 with Prescription Drug User Fee Act (PDUFA) target [...]
Human Appeal USA expands winter coat drive to six states
12/11/2026
Second annual campaign builds on 2,000 coats distributed in Baltimore last year, with plans to engage 40 collection partners and at least 300 volunteers MISSION VIEJO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Human [...]
Rakovina Therapeutics Expands Strategic Engagement with Renowned AI Drug Discovery Pioneer Dr. Artem Cherkasov
12/11/2026
World leader in AI drug discovery to take on an expanded strategic advisory role, supporting AI drug discovery strategy, technology assessment and corporate development opportunities VANCOUVER, British Columbia, Nov. 12 [...]
A Race Against Blindness Unveils Classic 1989 Toyota Land Cruiser Fundraiser to Advance Vision Research
12/11/2026
Iconic FJ62 Land Cruiser returns with modern upgrades in a $125,000 prize package supporting research for inherited retinal diseases GILBERT, Ariz., Nov. 12, 2026 (GLOBE NEWSWIRE) -- A Race Against Blindness is bringing [...]
Commit Biologics nominates first development candidate from BiCE™, its complement system engaging platform, and strengthens senior leadership
12/11/2026
COM002 is a first-in-class complement-powered immune engager based on Commit Biologics’ proprietary BiCE™ platform. Anne-Marie Levy Rasmussen appointed Chief Operating Officer and Dr. Benjamin Ole Wolthers as Head of [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum